-
Je něco špatně v tomto záznamu ?
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide
S. Piemontese, M. Labopin, G. Choi, AEC. Broers, J. Peccatori, E. Meijer, G. Van Gorkom, M. Rovira, MJ. Pascual Cascon, S. Sica, J. Vydra, A. Kulagin, A. Spyridonidis, A. Nagler, A. Bazarbachi, B. Savani, E. Brissot, J. Sanz, M. Mohty, F. Ciceri
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, srovnávací studie
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- akutní myeloidní leukemie * terapie mortalita farmakoterapie patologie MeSH
- cyklofosfamid * terapeutické užití aplikace a dávkování MeSH
- dospělí MeSH
- homologní transplantace MeSH
- indukce remise * MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- nemoc štěpu proti hostiteli etiologie MeSH
- nepříbuzný dárce MeSH
- příprava pacienta k transplantaci * metody MeSH
- prognóza MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk * metody MeSH
- věkové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
An increasing number of older patients with acute myeloid leukemia (AML) are offered an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Normally, older patients have older matched related donors (MRD). Matched unrelated donors (MUD) are an important alternative, but it remains unclear whether a younger MUD is associated with better outcomes, especially in the context of post-transplant cyclophosphamide (PTCy). We compared outcomes of patients older than 50 years with AML in first complete remission (CR1) and receiving a first HSCT from a 10/10 MUD aged younger than 40 years to those receiving a graft from a MRD aged older than 50 years, using PTCy and with well-known transplant conditioning intensity (TCI) score. A total of 345 consecutive patients were included and classified according to TCI score as low, intermediate, or high. On multivariable analysis in the TCI-intermediate/high group, MUD was associated with better graft-versus-host disease-free, relapse-free survival, lower non-relapse mortality and lower relapse incidence. For patients receiving a TCI-low regimen, outcomes are independent on the type of donor. In patients with AML in CR1, older than 50 years and receiving a TCI-intermediate/high conditioning regimen using PTCy, a MUD younger than 40 years is preferable over a MRD older than 50 years.
Bone Marrow Transplantation and Institute of Cell Therapy University of Patras Patras Greece
Department of Haematology Oncology Vanderbilt University Medical Center Nashville TN USA
Department of Hematology Amsterdam UMC location VU Amsterdam The Netherlands
Division of Hematology Sheba Medical Center Tel Hashomer Israel
EBMT Paris Office Hopital Saint Antoine Paris France
Erasmus MC Cancer Institute Rotterdam Rotterdam The Netherlands
Fondazione Policlinico Universitario A Gemelli IRCCS Roma Italy
Hematology and Bone Marrow Transplant Unit IRCCS San Raffaele Hospital Milan Italy
Hematology Hospital Regional de Málaga Malaga Spain
Hôpital Saint Antoine Sorbonne University INSERM UMRs 938 Paris France
Institute of Hematology and Blood Transfusion Prague Prague Czech Republic
Università Vita Salute San Raffaele Milan Italy
University Medical Center Groningen University of Groningen Groningen The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019083
- 003
- CZ-PrNML
- 005
- 20241024111616.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-024-02359-8 $2 doi
- 035 __
- $a (PubMed)39048722
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Piemontese, Simona $u Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Milan, Italy. piemontese.simona@hsr.it $1 https://orcid.org/0000000259080792
- 245 10
- $a Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide / $c S. Piemontese, M. Labopin, G. Choi, AEC. Broers, J. Peccatori, E. Meijer, G. Van Gorkom, M. Rovira, MJ. Pascual Cascon, S. Sica, J. Vydra, A. Kulagin, A. Spyridonidis, A. Nagler, A. Bazarbachi, B. Savani, E. Brissot, J. Sanz, M. Mohty, F. Ciceri
- 520 9_
- $a An increasing number of older patients with acute myeloid leukemia (AML) are offered an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Normally, older patients have older matched related donors (MRD). Matched unrelated donors (MUD) are an important alternative, but it remains unclear whether a younger MUD is associated with better outcomes, especially in the context of post-transplant cyclophosphamide (PTCy). We compared outcomes of patients older than 50 years with AML in first complete remission (CR1) and receiving a first HSCT from a 10/10 MUD aged younger than 40 years to those receiving a graft from a MRD aged older than 50 years, using PTCy and with well-known transplant conditioning intensity (TCI) score. A total of 345 consecutive patients were included and classified according to TCI score as low, intermediate, or high. On multivariable analysis in the TCI-intermediate/high group, MUD was associated with better graft-versus-host disease-free, relapse-free survival, lower non-relapse mortality and lower relapse incidence. For patients receiving a TCI-low regimen, outcomes are independent on the type of donor. In patients with AML in CR1, older than 50 years and receiving a TCI-intermediate/high conditioning regimen using PTCy, a MUD younger than 40 years is preferable over a MRD older than 50 years.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $x terapie $x mortalita $x farmakoterapie $x patologie $7 D015470
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a cyklofosfamid $x terapeutické užití $x aplikace a dávkování $7 D003520
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a indukce remise $7 D012074
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a nepříbuzný dárce $7 D061349
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a homologní transplantace $7 D014184
- 650 _2
- $a nemoc štěpu proti hostiteli $x etiologie $7 D006086
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Labopin, Myriam $u EBMT Paris Office, Hopital Saint Antoine, Paris, France
- 700 1_
- $a Choi, Goda $u University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Broers, Annoek E C $u Erasmus MC Cancer Institute - Rotterdam, Rotterdam, The Netherlands
- 700 1_
- $a Peccatori, Jacopo $u Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Milan, Italy
- 700 1_
- $a Meijer, Ellen $u Department of Hematology, Amsterdam UMC, location VU, Amsterdam, The Netherlands
- 700 1_
- $a Van Gorkom, Gwendolyn $u Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
- 700 1_
- $a Rovira, Montserrat $u BMT Unit, Haematology Department, Hospital Clinic, IDIBAPS and Josep Carreras Foundation, Barcelona, Spain
- 700 1_
- $a Pascual Cascon, Maria Jesús $u Hematology, Hospital Regional de Málaga, Malaga, Spain
- 700 1_
- $a Sica, Simona $u Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
- 700 1_
- $a Vydra, Jan $u Institute of Hematology and Blood Transfusion - Prague, Prague, Czech Republic
- 700 1_
- $a Kulagin, Alexander $u RM Gorbacheva Research Institute, Pavlov University - Saint Petersburg, Saint Petersburg, Russian Federation $1 https://orcid.org/0000000295894136
- 700 1_
- $a Spyridonidis, Alexandros $u Bone Marrow Transplantation and Institute of Cell Therapy, University of Patras, Patras, Greece $1 https://orcid.org/0000000330972532
- 700 1_
- $a Nagler, Arnon $u Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
- 700 1_
- $a Bazarbachi, Ali $u Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon $1 https://orcid.org/0000000271714997
- 700 1_
- $a Savani, Bipin $u Department of Haematology-Oncology, Vanderbilt University, Medical Center, Nashville, TN, USA $1 https://orcid.org/0000000233049965 $7 xx0317726
- 700 1_
- $a Brissot, Eolia $u Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs, 938, Paris, France $1 https://orcid.org/000000034471418X
- 700 1_
- $a Sanz, Jaime $u Hospital Universitari i Politècnic La Fe, Hematology Department, Departament de Medicina Universitat de Valencia, Valencia, Spain
- 700 1_
- $a Mohty, Mohamad $u Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs, 938, Paris, France
- 700 1_
- $a Ciceri, Fabio $u Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Milan, Italy $u Università Vita-Salute San Raffaele, Milan, Italy
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 38, č. 9 (2024), s. 2016-2022
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39048722 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111610 $b ABA008
- 999 __
- $a ok $b bmc $g 2201729 $s 1231056
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 9 $d 2016-2022 $e 20240724 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20241015
